In vivo, light-activated CX-5461 suppresses tumor growth and extends survival in immunocompetent syngeneic models, eliciting hallmarks consistent with immunogenic genome stress, and supporting a model in which broader oxidative DNA damage may also contribute to the biological response.
Abstract
Abstract CX-5461 (pidnarulex) is the most clinically advanced small-molecule ligand associated with G-quadruplex (G4) targeting and shows activity in DNA repair–deficient tumors, yet its clinical use is associated with dose-limiting phototoxicity. Here, we repurpose this intrinsic photoreactivity to investigate CX-5461 as a G4-associated, light-activated antitumor scaffold. In solution, CX-5461 produces both Type I and Type II reactive oxygen species (ROS), whereas complexation with G4 DNA markedly decreases detectable singlet oxygen (1O2) formation and favors radical-associated Type I oxidation. This G4-modulated photochemical shift drives oxidative remodeling and destabilization of G4-containing DNA. In cancer cells, photoactivation enhances cytotoxicity by up to two orders of magnitude relative to the dark state and is accompanied by elevated intracellular ROS, increased 8-oxoG formation, γ-H2AX accumulation, and changes in BG4-detected nuclear G4 structures. In vivo, light-activated CX-5461 suppresses tumor growth and extends survival in immunocompetent syngeneic models, eliciting hallmarks consistent with immunogenic genome stress. Collectively, these findings reposition CX-5461 as a clinically relevant scaffold for G4-associated photogenomic cancer therapy, while supporting a model in which broader oxidative DNA damage may also contribute to the biological response.
RS-04 achieved potent tumor growth inhibition with markedly reduced systemic toxicity compared to the physical combination of its parent drugs, highlighting the clinical potential of utilizing the Pt (IV) framework as a sophisticated delivery vehicle to synchronize DNA damage with innate immune activation for superior...
Jun-Kang Ren, Jia-Ni Wu, Xin-Yu Dai et al.· European journal of medicina...· 0 citations
Mitochondria are emerging as critical hubs for cancer therapeutics, yet the development of agents that simultaneously enable real-time imaging and targeted therapy remains a formidable challenge. Here we report LN1, a smart theranostic small molecule designed to selectively target mitochondrial G-quadruplex (mtG4) DNA...
Nuan Li, Wen-Bo Yan, Zhe Wang et al.· Spectrochimica Acta Part A -...· 0 citations
The first example of a histone deacetylase-activatable G4 ligand, displaying a significant stabilization upon activation (26 °C, ΔTm), was developed and has a promising therapeutic potential and can be a useful building block for the development of novel activatable G-quadruplex ligands.
Dye 11f (meta-dimethoxy) emerged as the lead compound, combining strong fluorogenic response, brightness, stability, rapid membrane permeability, and low cytotoxicity.
Devorah Corn, Alon Boocholez, Prasenjit Das et al.· Journal of Medicinal Chemist...· 0 citations
This work supports mtDNA G4-associated recognition as a strategy for improving the subcellular precision of PDT and provides a generalizable framework for developing mitochondria-directed phototherapies.
It is demonstrated that CX-5461 appears as highly potent G4-ligand inducing p53-dependent molecular cascades leading to cell death in germ cell tumors.
Rashidul Islam, Annalena Liesen, C. S. R. Roque et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.